Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MREO Mereo BioPharma Group	$2.88 +0.2%	$2.55	$1.58 ▼ $5.02	$456.33M	0.46	1.09 million shs	799,203 shs
RGNX REGENXBIO	$8.73 +1.3%	$8.99	$5.04 ▼ $15.36	$438.40M	1.06	930,242 shs	423,944 shs
THTX Theratechnologies	$3.13 +32.6%	$2.61	$1.12 ▼ $3.20	$147.14M	0.55	864,044 shs	10.56 million shs
TRML Tourmaline Bio	$16.78 +3.6%	$16.81	$11.56 ▼ $29.79	$421.75M	2	256,004 shs	59,085 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MREO Mereo BioPharma Group	0.00%	+8.08%	+16.87%	+44.47%	-19.92%
RGNX REGENXBIO	0.00%	+4.05%	+4.43%	+38.79%	-19.32%
THTX Theratechnologies	0.00%	+33.19%	+19.01%	+111.49%	+131.85%
TRML Tourmaline Bio	0.00%	+1.42%	-11.20%	+30.75%	+30.75%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MREO Mereo BioPharma Group	1.9659 of 5 stars	3.6	3.0	0.0	0.0	0.6	1.7	0.0
RGNX REGENXBIO	4.5312 of 5 stars	3.4	3.0	0.0	4.6	2.3	3.3	0.6
THTX Theratechnologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRML Tourmaline Bio	2.1311 of 5 stars	3.5	3.0	0.0	0.0	0.6	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MREO Mereo BioPharma Group	3.20	Buy	$7.60	164.35% Upside
RGNX REGENXBIO	2.83	Moderate Buy	$31.63	262.26% Upside
THTX Theratechnologies	3.00	Buy	N/A	N/A
TRML Tourmaline Bio	3.00	Buy	$49.33	194.09% Upside

Current Analyst Ratings Breakdown

Latest THTX, TRML, MREO, and RGNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/3/2025	THTX Theratechnologies	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/9/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00
5/13/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
5/5/2025	TRML Tourmaline Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $70.00
5/5/2025	TRML Tourmaline Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
4/23/2025	TRML Tourmaline Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$70.00
4/17/2025	RGNX REGENXBIO	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$14.00 ➝ $12.00
4/11/2025	THTX Theratechnologies	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
4/9/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MREO Mereo BioPharma Group	$10M	45.71	N/A	N/A	$0.39 per share	7.37
RGNX REGENXBIO	$156.72M	2.79	N/A	N/A	$5.24 per share	1.67
THTX Theratechnologies	$88.67M	1.62	N/A	N/A	($0.55) per share	-5.69
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	$11.71 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MREO Mereo BioPharma Group	-$43.25M	-$0.07	N/A	N/A	N/A	N/A	-69.33%	-57.27%	8/12/2025 (Estimated)
RGNX REGENXBIO	-$227.10M	-$3.11	N/A	N/A	N/A	-100.62%	-53.29%	-30.84%	8/7/2025 (Estimated)
THTX Theratechnologies	-$8.31M	-$0.08	N/A	44.71	N/A	-4.18%	N/A	-0.37%	7/9/2025 (Estimated)
TRML Tourmaline Bio	-$73.21M	-$3.21	N/A	N/A	N/A	N/A	-26.75%	-26.11%	8/6/2025 (Estimated)

Latest THTX, TRML, MREO, and RGNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	MREO Mereo BioPharma Group	-$0.01	-$0.02	-$0.01	-$0.02	$72.50 million	N/A
5/12/2025	Q1 2025	RGNX REGENXBIO	$0.41	$0.12	-$0.29	$0.12	$105.35 million	$89.01 million
5/2/2025	Q1 2025	TRML Tourmaline Bio	-$0.91	-$0.89	+$0.02	-$0.89	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MREO Mereo BioPharma Group	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A
THTX Theratechnologies	N/A	N/A	N/A	N/A	N/A
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MREO Mereo BioPharma Group	N/A	8.92	8.92
RGNX REGENXBIO	N/A	2.93	2.93
THTX Theratechnologies	N/A	1.08	0.88
TRML Tourmaline Bio	N/A	33.87	33.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MREO Mereo BioPharma Group	62.83%
RGNX REGENXBIO	88.08%
THTX Theratechnologies	N/A
TRML Tourmaline Bio	91.89%

Insider Ownership

Company	Insider Ownership
MREO Mereo BioPharma Group	5.50%
RGNX REGENXBIO	12.79%
THTX Theratechnologies	N/A
TRML Tourmaline Bio	13.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MREO Mereo BioPharma Group	40	159.00 million	150.26 million	Optionable
RGNX REGENXBIO	370	50.16 million	43.75 million	Optionable
THTX Theratechnologies	140	45.98 million	N/A	Optionable
TRML Tourmaline Bio	44	25.68 million	22.35 million	Optionable

THTX, TRML, MREO, and RGNX Headlines

Recent News About These Companies

Tourmaline Bio Inc News (TRML) - Investing.com

July 3 at 3:49 PM | investing.com

Tourmaline Bio, Inc. (NASDAQ:TRML) Receives $49.33 Average Price Target from Analysts

June 27, 2025 | americanbankingnews.com

TRML - Tourmaline Bio Inc Dividends - Morningstar

June 26, 2025 | morningstar.comM

TRML - Tourmaline Bio Inc Executives - Morningstar

June 24, 2025 | morningstar.comM

Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Rating of "Buy" from Brokerages

June 24, 2025 | marketbeat.com

Cantor Fitzgerald Weighs in on Tourmaline Bio FY2026 Earnings

June 11, 2025 | marketbeat.com

Two Sigma Investments LP Sells 21,904 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML)

June 10, 2025 | marketbeat.com

Tourmaline Bio Elects Directors and Ratifies Auditor

June 6, 2025 | tipranks.com

Tourmaline Bio, Inc. (NASDAQ:TRML) Shares Bought by Bank of America Corp DE

June 6, 2025 | marketbeat.com

H.C. Wainwright maintains $50 target on Tourmaline Bio stock

May 29, 2025 | uk.investing.com

H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results

May 29, 2025 | msn.com

BMO Sees Overreaction, Maintains Rating and Price Target on Tourmaline Bio (TRML)

May 23, 2025 | msn.com

Tourmaline shares waver as investors mull mid-stage pacibekitug data

May 21, 2025 | thepharmaletter.comT

Tourmaline touts cardiovascular potential of former Pfizer antibody after phase 2 kidney disease win

May 20, 2025 | fiercebiotech.comF

Tourmaline Bio posts mid-stage data for anti-inflammatory agent

May 20, 2025 | msn.com

Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition

May 20, 2025 | seekingalpha.com

Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

May 19, 2025 | globenewswire.com

Tourmaline Bio Reports Q1 2025 Financial Results

May 7, 2025 | tipranks.com

Why Tourmaline Bio, Inc.’s (TRML) Stock Is Down 7.00%

May 3, 2025 | aaii.comA

Tourmaline Bio, Inc.: Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 3, 2025 | finanznachrichten.de

Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 2, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

THTX, TRML, MREO, and RGNX Company Descriptions

Mereo BioPharma Group NASDAQ:MREO

$2.88 +0.01 (+0.17%)

Closing price 07/3/2025 03:55 PM Eastern

Extended Trading

$2.88 0.00 (0.00%)

As of 07/3/2025 04:15 PM Eastern

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

REGENXBIO NASDAQ:RGNX

$8.73 +0.11 (+1.28%)

Closing price 07/3/2025 03:52 PM Eastern

Extended Trading

$8.74 +0.00 (+0.06%)

As of 07/3/2025 04:33 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Theratechnologies NASDAQ:THTX

$3.13 +0.77 (+32.63%)

Closing price 07/3/2025 03:59 PM Eastern

Extended Trading

$3.16 +0.02 (+0.80%)

As of 07/3/2025 04:56 PM Eastern

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Tourmaline Bio NASDAQ:TRML

$16.77 +0.59 (+3.61%)

Closing price 07/3/2025 03:43 PM Eastern

Extended Trading

$16.82 +0.04 (+0.24%)

As of 07/3/2025 04:30 PM Eastern

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time